Article Text

Download PDFPDF
Hydroxycarbamide (hydroxyurea) for children aged 9–18 months with sickle cell disease

Statistics from

Archivist has never really got to grips with the compulsion common to chemists and microbiologists for changing long-established names. For instance, a recent paper on hydroxycarbamide for the treatment of sickle cell disease in young children (Winifred C Yang and colleagues. Lancet 2011;377:1663–72; see also Comment, ibid) gives 22 references that include the name of the drug in the title, and in every one of the titles, the name used is hydroxyurea. In the text of the article, the names …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.